← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
The Methodist Hospital Research Institute
Houston, TX
$47,832,027
Total funding
55
Grants
Funding over time
peak $9.8M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$43,612,052 · 39
NSF$3,560,634 · 14
NASA$659,341 · 2
By mechanism
—$47,832,027 · 55
Investigators at The Methodist Hospital Research Institute
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
A GMP/GLP INVESTIGATION OF DEGRADABLE POLYMERIC SHELLS FOR TRAUMATIC OSTEOREGENERATION$8,302,418
· FY2015 · Defense Health Agency
TOWARD INDIVIDUALIZED BREAST CANCER THERAPY: LEVERAGING MOLECULAR MEDICINE WITH MULTISTAGE VECTOR TECHNOLOGY$7,362,314
· FY2009 · Department of Defense
ANH TATRC 2010 PRE CENTER AND SEED GRANTS$3,460,140
· FY2011 · Department of Defense
MULTISTAGE VECTOR-ENABLED BREAST ONCOLOGY$3,110,000
· FY2012 · Department of the Army
ALLIANCE FOR NANOHEALTH COMPETITIVE RESEARCH PROGRAM FY2009$2,802,000
· FY2010 · Department of Defense
NANOTECHNOLOGY-BASED TARGETING OF BREAST CANCER LIVER METASTASES$1,558,965
· FY2021 · Defense Health Agency
TRANSFORMING TRIPLE-NEGATIVE BREAST CANCER TREATMENT THROUGH INTRATUMORAL IMMUNOTHERAPY VIA NANOFLUIDIC DRUG-ELUTING SEED$1,404,919
· FY2020 · Defense Health Agency
NANO-IMAGING AGENTS FOR EARLY DISEASE DETECTION$1,401,000
· FY2010 · Department of the Army
DEVELOPMENT OF A NOVEL THERAPEUTIC TO TREAT DNA DAMAGE ASSOCIATED WITH ATYPICAL BURNS$1,400,000
· FY2024 · Defense Health Agency
COMPUTER-BASED TRAINING METHODS FOR SURGICAL TESTING$838,812
· FY2008 · Department of the Army
TRANSFORMING TRIPLE-NEGATIVE BREAST CANCER TREATMENT THROUGH INTRATUMORAL IMMUNOTHERAPY VIA NANOFLUIDIC DRUG-ELUTING SEED$834,791
· FY2020 · Defense Health Agency
NY-ESO-1-SPECIFIC TCR-ENGINEERED T CELL IMMUNOTHERAPY FOR TRIPLE NEGATIVE BREAST CANCER$828,577
· FY2016 · Defense Health Agency
BIONANOSCAFFOLDS (BNS) FOR POST-TRAUMATIC OSTEOREGENERATION MODULE I: RESTORED MECHANICAL AND AMBULATORY FUNCTION$824,993
· FY2011 · Department of the Army
MITIE TELEMENTORING PLATFORM: A NOVEL TRANSPORTABLE, AND MOBILE TELEMEDICINE PLATFORM FOR COMMUNICATION$724,560
· FY2009 · Department of the Army
NANOMEDICINE FOR EARLY DISEARS DETECTION AND TREATMENT$699,000
· FY2011 · Department of Defense
I/UCRC: Full Center Grant: I/UCRC for Cyber-Physical Systems for the Hospital Operating Room$674,995
· FY2015 · CSE
ABROGATING COLLAGEN SIGNALING TO LIBERATE ANTITUMORAL T CELLS TO IMPROVE THERAPEUTIC RESPONSE$667,909
· FY2022 · Defense Health Agency
HOME NEUROMODULATION FOR NEUROGENIC BLADDER MANAGEMENT IN SPINAL CORD INJURY: A HYBRID IMPLEMENTATION-EFFICACY TRIAL$662,742
· FY2025 · Defense Health Agency
NANOVECTORS FOR TARGETING AND DELOVERY OF THERAPEUTICS TO HER-2 NEU POSITIVE BREAST CANCER CELLS$658,440
· FY2008 · Department of the Army
REPROGRAMMING PROTUMORAL NEUTROPHILS TO ENHANCE ICI-BASED RESPONSES IN BLADDER CANCER$646,000
· FY2025 · Defense Health Agency